Atlas Trials

A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors

Clinical trial NCT00002235 · COMPLETED

Trial details

NCT number
NCT00002235
Sponsor
Merck Sharp & Dohme LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HIV Infections
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.